Ian Macara, PhD, Louise B. McGavock Professor and Chair of Cell and Developmental Biology and co-leader of the Signal Transduction and Chemical Biology Research Program at Vanderbilt-Ingram Cancer Center (VICC), has been named one of the Pink Tie Guys for the Susan G. Komen Central Tennessee organization.
News: Breast Cancer
Amanda Mathis went from being a patient at Vanderbilt-Ingram Cancer Center to becoming a member of the cancer center’s Board of Overseers.
Tuya Pal, M.D., associate professor of medicine and Ingram Associate Professor of Cancer Research., specializes in cancer genetics and health disparities among diverse populations.
Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.
Three breast cancer investigators from Vanderbilt-Ingram Cancer Center (VICC) have been awarded research grants from Susan G. Komen, a nonprofit foundation devoted to supporting cancer research, community health outreach, advocacy and public policy initiatives.
Health & Wellness would like to celebrate you and support breast cancer awareness by creating an “Awareness Saves Lives” faculty and staff survivor banner. The banner will be displayed as part of the 2017 Breast Cancer Awareness Expo scheduled for Oct. 4 from 11 a.m. to 1 p.m. in the Light Hall North Lobby.
Thanks to advances in treatment, the relative five-year survival rate from all combined subtypes of breast cancer now exceeds 90 percent and yet the disease remains the third leading cause of cancer deaths in the United States after lung and colorectal cancers. Carlos L. Arteaga, M.D. More than 40,000 American women will die from breast […]
Stress stimulates the formation of blood vessels in bone and may help breast cancer cells to invade this organ. In the July issue of the Journal of Bone and Mineral Research, Florent Elefteriou, Ph.D., Julie A. Sterling, Ph.D., and colleagues describe a mechanism for skeletal colonization by breast cancer cells that could lead to new ways to […]
Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. They identified a novel gene mutation that develops in the tumors, and then found a different cancer drug that appears to treat the newly identified mutation. The […]
Overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 25 percent of breast cancers and is associated with poor outcomes. HER2-amplified breast cancers use signaling through a complex of proteins called mTORC2 to drive tumor formation, tumor cell survival and resistance to HER2-targeted therapies. Rebecca Cook, Ph.D., and colleagues have now […]